0000950170-24-053536.txt : 20240506 0000950170-24-053536.hdr.sgml : 20240506 20240506160518 ACCESSION NUMBER: 0000950170-24-053536 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20240502 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240506 DATE AS OF CHANGE: 20240506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLASE, INC CENTRAL INDEX KEY: 0000811240 STANDARD INDUSTRIAL CLASSIFICATION: DENTAL EQUIPMENT & SUPPLIES [3843] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 870442441 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36385 FILM NUMBER: 24917470 BUSINESS ADDRESS: STREET 1: 27042 TOWNE CENTRE DRIVE STREET 2: SUITE 270 CITY: FOOTHILL RANCH STATE: CA ZIP: 92610 BUSINESS PHONE: 949-361-1200 MAIL ADDRESS: STREET 1: 27042 TOWNE CENTRE DRIVE STREET 2: SUITE 270 CITY: FOOTHILL RANCH STATE: CA ZIP: 92610 FORMER COMPANY: FORMER CONFORMED NAME: BIOLASE TECHNOLOGY INC DATE OF NAME CHANGE: 19941117 FORMER COMPANY: FORMER CONFORMED NAME: LASER MEDICAL TECHNOLOGY INC DATE OF NAME CHANGE: 19941117 FORMER COMPANY: FORMER CONFORMED NAME: LASER ENDO TECHNIC CORP DATE OF NAME CHANGE: 19920708 8-K 1 biol-20240502.htm 8-K 8-K
0000811240false00008112402024-05-022024-05-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): May 2, 2024

BIOLASE, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-36385

87-0442441

(State or other jurisdiction of incorporation)

(Commission File No.)

(IRS Employer Identification No.)

27042 Towne Centre Drive, Suite 270

Lake Forest, California 92610

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (949) 361-1200

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

BIOL

The Nasdaq Stock Market LLC

(Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

1

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

On May 2, 2024, BIOLASE, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”). The following are the results of the voting on the ten (10) proposals (the “Proposals”) submitted to stockholders at the 2024 Annual Meeting. These Proposals are described in detail in the Company’s definitive proxy statement on Schedule 14A (the “Proxy Statement”) for the 2024 Annual Meeting, which was filed on March 22, 2024 with the Securities and Exchange Commission.

Proposal 1 – Stockholders elected each of the Company’s seven nominees for director, as set forth below:

 

Nominee

 

For

 

Against

 

Abstain

 

Broker Non-Votes

John R. Beaver

 

3,569,703

 

921,963

 

555,123

 

6,214,310

Jonathan T. Lord, M.D.

 

3,608,250

 

872,298

 

566,241

 

6,214,310

Kathleen T. O’Loughlin, D.D.S.

 

3,613,991

 

868,497

 

564,301

 

6,214,310

Martha Somerman, D.D.S.

 

3,615,973

 

866,754

 

564,062

 

6,214,310

Kenneth Yale, D.D.S., J.D.

 

3,615,441

 

862,385

 

568,963

 

6,214,310

 

Proposal 2 – Stockholders voted, on an advisory basis, to approve the compensation of the Company’s named executive officers, as set forth below:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

2,887,340

 

1,614,144

 

545,305

 

6,214,310

 

Proposal 3 – Stockholders voted, on an advisory basis, to approve the frequency of future stockholder advisory votes on the compensation of the Company’s named executive officers every year, as set forth below:

 

One Year

 

Two Years

 

Three Years

 

Against

 

Broker Non-Votes

3,998,225

 

87,350

 

211,551

 

749,663

 

6,214,310

Based on the recommendations of the Company’s Board of Directors and its Compensation Committee to hold advisory votes on executive compensation every year and the vote of the stockholders on this matter (as set forth above), the Company has decided that an advisory stockholder vote on executive compensation will be held every year until the next advisory vote on the frequency of future stockholder advisory votes on executive compensation.

Proposal 4 – Stockholders voted to approve the exercise of warrants issued on December 8, 2023 to purchase up to 2,221,880 shares of common stock under applicable rules and regulations of the Nasdaq Stock Market, as set forth below:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

3,519,468

 

1,110,299

 

417,022

 

6,214,310

Proposal 5 – Stockholders voted to approve the exercise of warrants issued on February 15, 2024 to purchase up to 2,221,880 shares of common stock under applicable rules and regulations of the Nasdaq Stock Market, as set forth below:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

3,509,296

 

1,120,469

 

417,024

 

6,214,310

 

Proposal 6 – Stockholders voted to approve the exercise of Class B warrants issued on February 15, 2024 to purchase up to 16,000,000 shares of common stock under applicable rules and regulations of the Nasdaq Stock Market,as set forth below:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

3,503,157

 

1,133,043

 

410,589

 

6,214,310

 

Proposal 7 – Stockholders did not approve an amendment to the BIOLASE, Inc. 2018 Long-Term Incentive Plan (the “2018 LTIP”) to increase the number of shares of the Company’s common stock available for issuance under the 2018 LTIP by an additional 7,500,000 shares, as set forth below:

2

 

For

 

Against

 

Abstain

 

Broker Non-Votes

2,459,084

 

2,050,644

 

537,061

 

6,214,310

Proposal 8 – Stockholders ratified the appointment of Macias Gini & O’Connell LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024, as set forth below:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

9,290,250

 

1,173,985

 

796,864

 

—

 

Proposal 9 – Stockholders voted to approve an amendment to the Company’s Restated Certificate of Incorporation, in substantially the form attached to the Proxy Statement as Exhibit B, to, at the discretion of the Board of the Company (the “Board”), effect a reverse stock split with respect to the Company’s issued and outstanding common stock, including stock held by the Company as treasury shares, at a ratio of 1-for-2 to 1-for-50 (the “Range”), with the ratio within such Range (the “Reverse Stock Split Ratio”) to be determined at the discretion of the Board and included in a public announcement, as set forth below:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

7,710,033

 

3,200,203

 

350,863

 

—

Proposal 10 – Stockholders voted to approve an adjournment of the 2024 Annual Meeting to a later date, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of Proposal Nos. 4, 5, 6 and 9, as set forth below:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

8,119,304

 

2,464,172

 

677,623

 

—

 

Item 9.01.

Financial Statements and Exhibits.

d) Exhibits.

 

Exhibit Number

 

Description

 104

 

Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

 

 

3

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

BIOLASE, INC.

 

 

 

Date: May 6, 2024

 

By:

 

/s/ John R. Beaver

 

Name:

 

John R. Beaver

 

Title:

 

Chief Executive Officer

 

4

 EX-101.SCH 2 biol-20240502.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, State or Province Entity Address, State or Province Trading Symbol Trading Symbol Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Written Communications Written Communications Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Registrant Name Entity Registrant Name Entity Information, Former Legal or Registered Name Entity Information, Former Legal or Registered Name Document Period End Date Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number City Area Code City Area Code Pre-commencement Tender Offer Pre-commencement Tender Offer Cover [Abstract] Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Amendment Flag Amendment Flag Securities Act File Number Entity File Number Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Title of 12(b) Security Title of 12(b) Security Document Type Document Type XML 4 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document and Entity Information
May 02, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 02, 2024
Trading Symbol BIOL
Entity Registrant Name BIOLASE, INC.
Entity Central Index Key 0000811240
Entity Emerging Growth Company false
Title of 12(b) Security Common Stock, par value $0.001 per share
Security Exchange Name NASDAQ
Entity File Number 001-36385
Entity Tax Identification Number 87-0442441
Entity Address, Address Line One 27042 Towne Centre Drive
Entity Address, Address Line Two Suite 270
Entity Address, City or Town Lake Forest
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92610
City Area Code 949
Local Phone Number 361-1200
Entity Incorporation, State or Country Code DE
Entity Information, Former Legal or Registered Name N/A
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
EXCEL 5 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 6 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 7 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 9 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.biolase.com/20240502/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports biol-20240502.htm biol-20240502.xsd http://xbrl.sec.gov/dei/2023 false false JSON 11 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "biol-20240502.htm": { "nsprefix": "biol", "nsuri": "http://www.biolase.com/20240502", "dts": { "inline": { "local": [ "biol-20240502.htm" ] }, "schema": { "local": [ "biol-20240502.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://www.biolase.com/20240502/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_ccdff933-2c1c-4232-8bba-ecdd752574df", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "biol-20240502.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ccdff933-2c1c-4232-8bba-ecdd752574df", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "biol-20240502.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.biolase.com/20240502/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "verboseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.biolase.com/20240502/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.biolase.com/20240502/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.biolase.com/20240502/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "verboseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.biolase.com/20240502/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.biolase.com/20240502/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.biolase.com/20240502/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.biolase.com/20240502/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.biolase.com/20240502/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.biolase.com/20240502/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.biolase.com/20240502/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.biolase.com/20240502/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.biolase.com/20240502/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": [ "http://www.biolase.com/20240502/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "verboseLabel": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.biolase.com/20240502/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.biolase.com/20240502/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.biolase.com/20240502/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.biolase.com/20240502/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "verboseLabel": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.biolase.com/20240502/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "verboseLabel": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.biolase.com/20240502/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.biolase.com/20240502/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.biolase.com/20240502/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "verboseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.biolase.com/20240502/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.biolase.com/20240502/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "verboseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 12 0000950170-24-053536-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-053536-xbrl.zip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biol-20240502_htm.xml IDEA: XBRL DOCUMENT 0000811240 2024-05-02 2024-05-02 0000811240 false 8-K 2024-05-02 BIOLASE, INC. DE 001-36385 87-0442441 27042 Towne Centre Drive Suite 270 Lake Forest CA 92610 949 361-1200 N/A false false false false Common Stock, par value $0.001 per share BIOL NASDAQ false